PathAI AISight vs Vesta
PathAI's buyer is a hospital pathology department moving to a cloud image management system, and the contract covers image management and primary diagnosis review. Roche signed on May 7, 2026 to acquire PathAI for $750M upfront plus up to $300M in milestones, with closing expected in the second half of 2026. AISight Dx was cleared as K243391 in June 2025 for FFPE primary diagnosis. Quest bought PathAI's clinical lab in June 2024.
Valar Labs raised a $22M Series A on May 22, 2024, co-led by DCVC and a16z with Pear VC participating. Valar puts the Vesta turnaround at about three days from sample receipt. Its product page carries vendor-selected testimonials from a UTMB urologist and from Mercy Clinic and Stanford Health Care.
A pathology department signs the PathAI contract, a urologist's office orders from Valar, and the two purchases are separate.
Pathology · Reviewed November 2, 2026
PathAI AISight
by PathAI · founded 2016
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
When to pick each one
PathAI AISight
- AISight Dx cleared, K243391, June 2025
- Roche partnership since 2021
Vesta
- CLIA-lab test, urologist orders it
- Report about 3 days after sample arrives, vendor says
Score
Each row shows points earned of points available under the published rubric.
PathAI AISight
40of 100
Vesta
16of 100
| Dimension | PathAI AISight | Vesta | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 8.4 / 21 | -8.4 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
PathAI AISight
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Billing period, trial and refund not stated. |
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
PathAI AISight
FDA decisions
K243391 (opens in new tab)510(k)2025-06-26
AISight Dx
K212361 (opens in new tab)510(k)2022-08-11
Novo
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | PathAI AISight | Vesta |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.